Regeneron Pharmaceuticals logo

Regeneron Pharmaceuticals

REGN | NASDAQ
Chart Builder DCF Calculator
$952.40
-$3.07 (-0.32%)
At close: Nov 16, 2026, 4:00 PM ET
$953.36
+$0.96 (+0.10%)
After-hours: Nov 16, 2026, 7:30 PM ET
-0.32%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
82.3
-0.2 pts
Fundamentals Excellent
Market Sentiment Bullish
Moat Wide
Sector Rank #12/1021 (Top 1%)

Why Price Moved

7 days ago
+1.73%

Shares are trading higher after positive CIDEB siR...

Key Statistics

Market Data

Market Cap $98.51B
1D Range
947.01 971.67
52W Range
600.66 973.36

Valuation (TTM)

PE 21.04
PB 2.94
EV/EBITDA 14.71

Valuation (NTM)

Forward PE 14.09
Forward PEG 0.36
Price Target $875.00
Loading financial charts...

Profile

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of ill...

Sector Healthcare
Industry Biotechnology
Employees 15,410
IPO Date Apr 2, 1991
Fiscal Year January - December

Latest News

REGN Price Forecast: Rally Faces Resistance After 37% Advance

8 hours ago · fxempire.com

REGN Price Forecast: Rally Faces Resistance After 37% Advance
Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?

2 days ago · fool.com

Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?
POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms

4 days ago · globenewswire.com

POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms
REGN Soars 27.4% in a Month: Buy, Sell or Hold the Stock?

4 days ago · zacks.com

REGN Soars 27.4% in a Month: Buy, Sell or Hold the Stock?
Why Regeneron (REGN) is a Top Value Stock for the Long-Term

5 days ago · zacks.com

Why Regeneron (REGN) is a Top Value Stock for the Long-Term
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Genetic Center and CIDEB siRNA Development for MASH Transcript

6 days ago · seekingalpha.com

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Genetic Center and CIDEB siRNA Development for MASH Transcript
Regeneron Pharmaceuticals Advances Liver Drug After Early Trial Cuts Liver Fat by Up to 80%

6 days ago · marketbeat.com

Regeneron Pharmaceuticals Advances Liver Drug After Early Trial Cuts Liver Fat by Up to 80%
CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD

8 days ago · globenewswire.com

CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD
Why Regeneron (REGN) Might be Well Poised for a Surge

13 days ago · zacks.com

Why Regeneron (REGN) Might be Well Poised for a Surge
REGN vs. ILMN: Which Stock Is the Better Value Option?

13 days ago · zacks.com

REGN vs. ILMN: Which Stock Is the Better Value Option?

Earnings

Latest Earnings
Oct 30, 2026
EPS
$20.07
Beat +21.56%
REV
$5.12B
Beat +11.59%
Next Earnings
Jan 28, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
25
Consensus
Buy
Price Target
$875.00
Downside
-8.13%
Buy (17)
Hold (8)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.